Cover Image


Global Cell Therapy Market Outlook 2020

出版商 KuicK Research 商品編碼 330564
出版日期 內容資訊 英文 550 Pages
商品交期: 最快1-2個工作天內
Back to Top
全球細胞療法市場預測:2020年 Global Cell Therapy Market Outlook 2020
出版日期: 2015年05月19日 內容資訊: 英文 550 Pages



第1章 細胞療法的簡介

第2章 細胞療法的分類

第3章 細胞療法的幹細胞所扮演的角色

第4章 細胞療法的作用機制

第5章 全球細胞療法市場分析

  • 目前市場方案
  • 細胞療法的臨床實驗平台概要

第6章 全球細胞療法市場趨勢

  • 有正面作用的市場參數
  • 商業化的課題

第7章 全球細胞療法市場未來發展預測

第8章 全球細胞療法的臨床實驗平台:各國、各適應症、各Phase

  • 不明
  • 研究階段
  • 前臨床
  • 臨床
  • 第0相
  • 第一階段
  • 第一階段/第二階段
  • 第二階段
  • 第二階段/第三階段
  • 第三階段
  • 認證前
  • 已認證

第9章 已上市細胞療法臨床考察:各品牌、各企業、各適應症

第10章 臨床實驗平台的中止、中斷的細胞療法

  • 未報告
  • 中止
  • 認證前:中止
  • 中斷

第11章 競爭情形

  • AlloCure
  • Arteriocyte Medical Systems
  • Athersys Inc.
  • Baxter Healthcare Corporation
  • Bone Therapeutics
  • Celgene Corporation
  • Cell Medica
  • Cellerant Therapeutics
  • FibrocellScinence
  • Forticell Bioscience
  • Genzyme Corporation
  • Green Cross Cell
  • Histogenics Corporation
  • InnovacellBiotechnologie AG
  • Intrexon Corporation
  • Intercytex
  • ISTO Technologies
  • Macrocure
  • Mesoblast
  • Molmed
  • Nuo Therapeutics Inc
  • OmniCyte
  • Opexa Therapeutics
  • Organogenesis
  • Pharmicell
  • TCA Cellular Therapy
  • Stem Cell Inc.
  • Teva Pharmaceuticals
  • Tigenix
  • Vericel Corporation



Pharmaceutical companies are actively looking for different modalities which could help in generating more revenues by competing with existing products. Traditional therapeutic have modest safety and efficacy levels and newer options are required to overcome their shortcomings. In this quest, they have focused upon cell therapy which holds both pharmacological and commercialization potential. Their utilization for therapeutic treatment of various diseases have been identified and used them successfully in past few decades. Various new cell therapy modalities are being discovered which are at different stages of clinical trials. They are expected to prove their safety and efficacy levels before entering in global market in coming years. Myriad of innovative cell therapies are under development which are expected to the change the way diseases are treated. Some of the therapeutics are widely accepted and they have already entered in clinical trials, while others are expected to face stringent regulations.

Cell therapies have been widely promoted by pharmaceutical companies as cure for all diseases. Especially, the concept of stem cell therapy has been promoted as panacea that can effectively tackle majority of ailments. But investigators have found that they are far from real scenario in which most of the underlying principles of stem cell therapy are not understood. During experimentation, investigators have found tumor formation in different parts of body of test subject. Microscopic examination revealed that it is not tumor nor cancerous cell accumulation, such thing has never been reported. In some cases, cancerous condition was found to be developed after administration of stem cells. These events show that server life threatening side effects could be developed without offering pharmacological benefits. Pharmaceutical companies need diligence because cells therapies are relatively new discovery and much work has to be done before their successful commercialization.

Utilization of cell therapy in tissue and regenerative medicine is expected to have huge marketing potential. Presently, there are no other options which could help in the growth of deregulated organs. Several therapeutic molecules are present in this segment but they are unable to form new tissue or sometimes organ transplant is required. It may be very complicated as suitable donor is required and process is quite invasive due to which high mortality rates are observed. On the other hand, cell therapy treatments are expected to overcome these issues which will increase their acceptance levels leading to higher sales. It could be applied for several categories that increase their applicability and commercialization prospects. Some categories like skin graft has been introduced across the globe for skin related issues. Presently, only few applications like severe burns are treated with their assistance but in future its applicability for cosmetic purposes are expected to be extended. In this way, their commercialization potential is expected to be improved increased due to increased number of indications.

Cell therapies are becoming competent with time and their utilization in large number of indications have made them an indispensible part of pharmaceutical industry. Significant investments in research and development segment along with years of data are helping in introduction of innovative products. However, they are quite new for pharmaceutical industry and their long-term effect is not known. It may offer hindrance but their superior pharmacological efficacy is going to promote their usage across the globe. It is at nascent stages but holds promise for future generations which are expected to observe boost in cell therapy products. Glitches in manufacturing and large scale production are needed to be solved in coming years. Many significant results have been achieved due to which confidence of investors, investigators, physicians and patients have increased in cell therapies. All these development shows that cell therapeutics are expected to generate significant revenues across the globe.

Global Cell Therapy Market Outlook 2020" Report Highlight:

  • Introduction & Classification of Cell Therapy
  • Role of Stem Cells in Cell Therapy
  • Global Cell Therapy Market Analysis
  • Global Cell Therapy Clinical Pipeline by Country, Indication & Phase
  • Marketed Cell Therapy Clinical Insight by Brand Name, Company & Indication
  • Global Cell Therapy Clinical Pipeline: 262 Cell Therapies
  • Marketed Cell Therapies: 13

Marketed Cell Therapy Clinical Insight by Brand Name, Company & Indication

  • Adipose Stem Cell Therapy (Adipocell®)
  • Allogeneic Cultured Keratinocytes & Fibroblasts (Gintuit®)
  • Angiogenic Cell Precursor Therapy (VesCell™)
  • Autologous Chondrocyte Implantation (ChondroCelect®)
  • Autologous Chondrocytes (BioCart™)
  • Autologous Cultured Chondrocyte Implant (Carticel®)
  • Autologous Cultured Chondrocytes (Chondrotransplant® DISC)
  • Matrix Characterised Autologous Cultured Chondrocytes (MACI™)
  • Azficel-T (Laviv®)
  • Human Skin Replacement for Burns (CellSpray®)
  • Leukocyte Cell Therapy (CureXcell™)
  • Sipuleucel-T (Provenge®)
  • T-Lymphocyte Cell Therapy (Immuncell-LC®)

Table of Contents

1. Introduction to Cell Therapy

2. Classification of Cell Therapies

3. Role of Stem Cells in Cell Therapy

  • 3.1 On the Basis of Ability to Differentiate
  • 3.2 On the Basis of Origin

4. Mechanism of Cell Therapy

5. Global Cell Therapy Market Analysis

  • 5.1 Current Market Scenario
  • 5.2 Cell Therapy Clinical Pipeline Overview

6. Global Cell Therapy Market Dynamics

  • 6.1 Favorable Market Parameters
  • 6.2 Commercialization Challenges

7. Global Cell Therapy Market Future Outlook

8. Global Cell Therapy Clinical Pipeline by Country, Indication & Phase

  • 8.1 Unknown
  • 8.2 Research
  • 8.3 Preclinical
  • 8.4 Clinical
  • 8.5 Phase-0
  • 8.6 Phase-I
  • 8.7 Phase-I/II
  • 8.8 Phase-II
  • 8.9 Phase-II/III
  • 8.10 Phase-III
  • 8.11 Preregistration
  • 8.12 Registered

9. Marketed Cell Therapy Clinical Insight by Brand Name, Company & Indication

  • 9.1 Adipose Stem Cell Therapy (Adipocell®)
  • 9.2 Allogeneic Cultured Keratinocytes & Fibroblasts (Gintuit®)
  • 9.3 Angiogenic Cell Precursor Therapy (VesCell™)
  • 9.4 Autologous Chondrocyte Implantation (ChondroCelect®)
  • 9.5 Autologous Chondrocytes (BioCart™)
  • 9.6 Autologous Cultured Chondrocyte Implant (Carticel®)
  • 9.7 Autologous Cultured Chondrocytes (Chondrotransplant® DISC)
  • 9.8 Matrix Characterised Autologous Cultured Chondrocytes (MACI™)
  • 9.9 Azficel-T (Laviv®)
  • 9.10 Human Skin Replacement for Burns (CellSpray®)
  • 9.11 Leukocyte Cell Therapy (CureXcell™)
  • 9.12 Sipuleucel-T (Provenge®)
  • 9.13 T-Lymphocyte Cell Therapy (Immuncell-LC®)

10. Discontinued & Suspended Cell Therapy in Clinical Pipeline

  • 10.1 No Development Reported
  • 10.2 Discontinued
  • 10.3 Preregistration-Submission Withdrawal
  • 10.4 Suspended

11. Competitive Landscape

  • 11.1 AlloCure
  • 11.2 Arteriocyte Medical Systems
  • 11.3 Athersys Inc.
  • 11.4 Baxter Healthcare Corporation
  • 11.5 Bone Therapeutics
  • 11.6 Celgene Corporation
  • 11.7 Cell Medica
  • 11.8 Cellerant Therapeutics
  • 11.9 FibrocellScinence
  • 11.10 Forticell Bioscience
  • 11.11 Genzyme Corporation
  • 11.12 Green Cross Cell
  • 11.13 Histogenics Corporation
  • 11.14 InnovacellBiotechnologie AG
  • 11.15 Intrexon Corporation
  • 11.16 Intercytex
  • 11.17 ISTO Technologies
  • 11.18 Macrocure
  • 11.19 Mesoblast
  • 11.20 Molmed
  • 11.21 Nuo Therapeutics Inc
  • 11.22 OmniCyte
  • 11.23 Opexa Therapeutics
  • 11.24 Organogenesis
  • 11.25 Pharmicell
  • 11.26 TCA Cellular Therapy
  • 11.27 Stem Cell Inc.
  • 11.28 Teva Pharmaceuticals
  • 11.29 Tigenix
  • 11.30 Vericel Corporation

List of Figures

  • Figure 1-1: Benefits of Cell Therapy
  • Figure 1-2: Few Important Diseases for which Cell Therapies are Being Developed
  • Figure 1-3: Limitation of Cell Therapies
  • Figure 2-1: Classification of Cell Therapy on the Basis of Origin of Cells
  • Figure 3-1: Type of Stem Cells on the Basis of Ability to Differentiate
  • Figure 3-2: Type of Stem Cells on the Basis of Origin
  • Figure 4-1: Steps Involved in Development of Cell Therapies
  • Figure 4-2: Mechanism of Bone Marrow Transplantation
  • Figure 4-3: Mechanism of Pancreatic Therapy
  • Figure 4-4: Mechanism of Cardiac Cell Therapy
  • Figure 5-1: Global Cell Therapy Market (US$ Billion), 2012-2020
  • Figure 5-2: Global Cell Therapy Clinical Pipeline by Phase (%), 2015
  • Figure 5-3: Global Cell Therapy Clinical Pipeline by Phase (Number), 2015
  • Figure 5-4: No Development Reported in Cell Therapy Clinical Pipeline by Phase (%), 2015
  • Figure 5-5: No Development Reported in Cell Therapy Clinical Pipeline by Phase (Number), 2015
  • Figure 5-6: Discontinued Cell Therapy Clinical Pipeline by Phase (%), 2015
  • Figure 5-7: Discontinued Cell Therapy Clinical Pipeline by Phase (Number), 2015
  • Figure 5-8: Suspended Cell Therapy Clinical Pipeline by Phase (%), 2015
  • Figure 5-9: Suspended Cell Therapy Clinical Pipeline by Phase (Number), 2015
  • Figure 6-1: Global Cell Therapy Market Favorable Parameters
  • Figure 6-2: Cell Therapy Commercialization Challenges
  • Figure 11-1: Arteriocyte Medical Systems Clinical Pipeline
  • Figure 11-2: Bone Therapeutics Clinical Pipeline
  • Figure 11-3: Celgene Clinical Pipeline
  • Figure 11-4: Cellerant Therapeutics Clinical Pipeline
  • Figure 11-5: Fibrocell Science Clinical Pipeline
  • Figure 11-6: Genzyme Clinical Pipeline
  • Figure 11-7: Intrexon Clinical Pipeline
  • Figure 11-8: ISTO Clinical Pipeline
  • Figure 11-9: Mesoblast Clinical Pipeline
  • Figure 11-10: Molmed Clinical Pipeline
  • Figure 11-11: Pharmicell Clinical Pipeline
  • Figure 11-12: Tigenix Clinical Pipeline
  • Figure 11-13: Vericel Corporation Clinical Pipeline

List of Tables

  • Table 2-1: Difference between Autogenic & Allogeneic Cell Therapy
  • Table 3-1: Difference between Embryonic, Adult & Induced Stem Cells
Back to Top